Csa Pharma Tech (Pvt) Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 18-12-2024
- Paid Up Capital ₹ 0.10 M
as on 18-12-2024
- Company Age 25 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 2.96%
(FY 2022)
- Profit 54.37%
(FY 2022)
- Ebitda -4870.39%
(FY 2022)
- Net Worth 4.22%
(FY 2022)
- Total Assets 6.89%
(FY 2022)
About Csa Pharma Tech (Pvt)
The Company is engaged in the Infrastructure And Utilities Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Umesh Aggarwal, Vandana Aggarwal, Yashsvi Aggarwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397DL1999PTC100586
- Company No.
100586
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jul 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Csa Pharma Tech (Pvt)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umesh Aggarwal  | Director | 08-Jul-1999 | Current |
| Vandana Aggarwal | Director | 15-Dec-1999 | Current |
| Yashsvi Aggarwal | Director | 10-May-2000 | Current |
| Dhruv Aggarwal | Director | 15-Apr-2011 | Current |
Financial Performance and Corporate Structure Insights of Csa Pharma Tech (Pvt).
Csa Pharma Tech (Pvt) Ltd, for the financial year ended 2022, experienced modest growth in revenue, with a 2.96% increase. The company also saw a substantial improvement in profitability, with a 54.37% increase in profit. The company's net worth moved up by a moderate rise of 4.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Csa Pharma Tech (Pvt)?
In 2021, Csa Pharma Tech (Pvt) had a promoter holding of 80.00% and a public holding of 20.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ambalika Holdings Private LimitedActive 28 years 7 monthsUmesh Aggarwal and Vandana Aggarwal are mutual person
- Frolic Pharmaceuticals Private LimitedActive 31 years 3 months
Umesh Aggarwal, Vandana Aggarwal and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Csa Pharma Tech (Pvt)?
Unlock and access historical data on people associated with Csa Pharma Tech (Pvt), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Csa Pharma Tech (Pvt), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Csa Pharma Tech (Pvt)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
